drugset
drugset / Trial / NCT01276119

The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males

NCT01276119 ↗

Phase 1 Completed 67 enrolled UCB Pharma
RandomizedParallel-groupTriple-blind

Summary

To evaluate the safety, tolerability, blood levels and effects of CDP6038 administered by intravenous infusion (iv) and subcutaneous (sc) injection.

Timeline

Start
2008-09
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Olokizumab Monoclonal antibody 0.001 mg/kg Intravenous
Subject Olokizumab Monoclonal antibody 0.01 mg/kg Intravenous
Subject Olokizumab Monoclonal antibody 0.03 mg/kg Intravenous
Subject Olokizumab Monoclonal antibody 0.1 mg/kg Intravenous
Subject Olokizumab Monoclonal antibody 0.3 mg/kg Intravenous
Subject Olokizumab Monoclonal antibody 1 mg/kg Intravenous
Subject Olokizumab Monoclonal antibody 3 mg/kg Intravenous
Subject Olokizumab Monoclonal antibody 10 mg/kg Intravenous

Indications

No indication recorded.